Welcome to our dedicated page for Allovir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on Allovir stock.
The AlloVir, Inc. (ALVR) news page on Stock Titan aggregates company communications and third-party coverage related to its activities as an allogeneic T cell immunotherapy developer and its planned merger with Kalaris Therapeutics, Inc. AlloVir describes itself as a late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised pediatric and adult patients. Its disclosures highlight an off-the-shelf, allogeneic virus-specific T cell platform and a pipeline led by the multi-virus-specific T cell therapy posoleucel.
Readers following ALVR news can find updates on clinical trial progress and outcomes, including Phase 2 and Phase 3 studies of posoleucel in allogeneic hematopoietic cell transplant recipients and adult kidney transplant recipients with BK viremia. Company releases have discussed prevention and treatment trials targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, and JC virus, as well as early-stage work on ALVR106 for respiratory viruses and ALVR107 for chronic hepatitis B infection.
News items also cover strategic and corporate developments. AlloVir has reported discontinuation of its three Phase 3 posoleucel studies after pre-planned futility analyses, along with a shift toward capital preservation and review of strategic alternatives. Subsequent announcements describe a definitive all-stock merger agreement with Kalaris Therapeutics, stockholder approval of that merger, and expectations that the combined company will operate as Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker KLRS, subject to customary closing conditions.
In addition, the ALVR news feed may include information on financings, investor conference participation, and regulatory designations such as RMAT, Orphan Drug, and PRIME status for posoleucel. Investors and researchers can use this page to monitor how AlloVir’s virus-specific T cell programs and its transition toward a retina-focused combined company with Kalaris are described over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AlloVir (NASDAQ: ALVR) announced the appointment of Dr. Derek Adams to its Board of Directors, effective March 1, 2023. With over two decades of experience in biologic and gene therapy manufacturing, Dr. Adams is expected to significantly contribute to AlloVir's ongoing Phase 3 studies of posoleucel and its commercialization efforts. This leadership change follows Dr. Ansbert Gadicke's decision to step down from the board after guiding the company since September 2018. Dr. Adams' extensive background in Chemistry, Manufacturing and Controls (CMC) will aid AlloVir in navigating regulatory complexities as it advances its cell therapy products.
AlloVir, Inc. (ALVR) announced the completion of enrollment for its posoleucel Phase 3 trials and positive results from its Phase 2 study in kidney transplant patients. The trials target three distinct indications, with data readouts expected in 2024. As of December 31, 2022, AlloVir reported a strong cash position of $233.8 million and a net loss of $168.7 million, equating to $2.20 per share. The company anticipates operating expenses between $150 million and $170 million for 2023. The firm is positioned for potential growth as it continues to advance its investigational therapies, particularly posoleucel, which aims to combat infections in immunocompromised patients.
AlloVir announced positive final results from a Phase 2 study of posoleucel for treating BK viremia in adult kidney transplant patients. The therapy was generally well tolerated, with a balanced safety profile across dosing groups and placebo. In a Week 24 analysis, 39% of posoleucel patients achieved a ≥1-log viral load reduction, significantly higher than the placebo's 14%. The biweekly dosing group showed a 50% reduction rate, while 69% of high viral load patients (≥10,000 copies/mL) achieved ≥1-log reductions. The data suggest posoleucel could offer a transformative treatment option for patients with unmet needs. The company plans further discussions with regulatory authorities.
AlloVir, Inc. (NASDAQ: ALVR) announced that CEO Diana Brainard, M.D., will engage in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00 a.m. ET. The event will be available via live webcast and archived replay on the Investors & Press section of AlloVir's website. AlloVir specializes in T-cell immunotherapy, focusing on treating patients with weakened immune systems. The company's innovative technology allows for the treatment of various viral diseases using allogeneic T cells. For updates, visit AlloVir's website.
AlloVir announced positive Phase 2 data for its investigational therapy posoleucel, presented at ASH 2022, highlighting its potential in multi-virus prevention. A global Phase 3 trial is ongoing, with completion of enrollment expected by the end of 2023. Topline data for the Phase 2 study in BKV treatment for kidney transplant patients is anticipated in Q1 2023. The company aims to advance its pipeline and reported a cash balance of
AlloVir, Inc. (NASDAQ: ALVR), a late-stage allogeneic T-cell immunotherapy company, announced that CEO Diana Brainard will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. PST in San Francisco. The event will be accessible via a live webcast and archived replay on AlloVir's website. AlloVir focuses on restoring immunity against life-threatening viral diseases using innovative T-cell therapies, and is advancing multiple clinical trials aimed at treating patients with weakened immune systems.